Biomarin Pharmaceutical’s Revenue by Segment (2016-2022)

This statistic highlights Biomarin Pharmaceutical’s Revenue by Segment, split between Net Product Revenue and Royalties and Other Revenues, reported on a quarterly basis from Q1 2016 onwards.

BioMarin Pharmaceutical Inc. is a global biotechnology company that develops and commercializes innovative therapies and treatments for people with serious and life-threatening rare diseases and medical conditions. They select product candidates for diseases and conditions that represent a significant unmet medical need, they have well-understood biology, and they provide an opportunity to be first-to-market or offer a significant benefit over existing products.

Biomarin Pharmaceutical’s Revenue by Segment

(All figures are in millions, except percentages)

BioMarin Pharmaceutical’s Revenue By Segment increases by YOY and QOQ basis. Earlier in Q3 2020 company holds a revenue of $476 million while in the next year Q3 2021 it falls to $409 million showing a decrease of 15%. The company’s Net product revenues segment shows revenue holding of 90%, while the Royalty and other revenues segment stands f0r only 10%, which is the lowest revenue shareholdings in the year 2021.

Net product revenues

Net sales refer to the total of the gross or total sales of a business while deducting or minus their returns, allowances, and discounts. Net calculations of the business sales are not always externally transparent. They can often be factored in while reporting on the statement of income along with the top-line revenues.

The company shows immense up and down in revenue by region in the Net product revenues segment.  Earlier in  Q3 2020 company holds a total of $460 million, while in the year Q2 2021 it rises to $486 million. This shows there 6% rise in revenue in this segment of the company. While in the year Q3 2021 it falls immensely to $394 million, which shows the total growth decreases by 19%.

Royalty and other revenues

The company shows immense up and down in revenue by region in the Latin America region.  Earlier in  Q3 2020, the company holds a total of $16 million, while in the year Q2 2021 it falls to $15 million. This shows there 7% fall in revenue in this segment of the company. While in the year Q3 2021 it remains same to $15 million.

About The Company

BioMarin is a global pharmaceutical company focused on developing first-class and best-in-class therapeutics that provide meaningful 0r relative advances to patients who live with serious and life threatening or rare genetic diseases. They remain steady fast to their original mission which is to bring new treatments to market that will make a big impact on small patient populations. These patient populations are mostly children or young ones, suffering from diseases that are so rare, that the entire patient population can number as few as 1,100 people worldwide. These conditions are often inherited, difficult to find or diagnose, progressively improving, if any, treatment options, and were usually ignored or not improved. Time is critical with patients having rare diseases, and they strive to quickly develop important or needy therapies for them.

The efficiency and speed of our research, development, manufacturing and commercial efforts are at the heart of their ability to urgently deliver therapies. Their track record of developing and commercializing new treatments has been significantly faster than the industry average and is a remarkable accomplishment that is ingrained in their culture. The company’s product portfolio comprises around five marketed products and has multiple clinical and pre-clinical product candidates.

Did you like Biomarin Pharmaceutical’s Revenue by Segment statistic?

Access more such key performance indicator (KPI) data points and segment financials, on thousands of US stocks, with Business Quant.

You can get started here.